MPS-112

MPS-112 is an orally available small molecule multi-kinase inhibitor developed by the Fondazione Ricerca Traslazionale (FoRT). It is designed to target the MET (Hepatocyte Growth Factor Receptor), ALK (Anaplastic Lymphoma Kinase), and ROS1 tyrosine kinases, which are frequently dysregulated in various malignancies, including non-small cell lung cancer (NSCLC). By inhibiting these kinases, MPS-112 blocks downstream signaling through the PI3K/AKT and MAPK/ERK pathways, thereby inhibiting tumor cell proliferation and survival. A Phase 1 clinical trial was initiated for patients with advanced solid tumors, including NSCLC, but the development appears to have been halted or terminated due to recruitment challenges.